Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janice M Reichert

Showing results (1-10 of 92) with videos related to

Pageof 10
Sort By:
Current Opinion in Molecular Therapeutics|June 5, 2002
Therapeutic monoclonal antibodies: trends in development and approval in the USJanice M Reichert
Medecine Sciences : M/S|January 7, 2020
[Antibody therapeutics: an American view of an amazing present and future]Janice M Reichert
Mabs|March 2, 2011
Letter from the Editor: stratified medicineJanice M Reichert
Mabs|June 10, 2011
Bispecific antibodies and ADCs: Once and future kings?Janice M Reichert
Mabs|January 13, 2010
Letter from the editorJanice M Reichert
Current Pharmaceutical Biotechnology|December 17, 2008
Monoclonal antibodies as innovative therapeuticsJanice M Reichert
Mabs|June 4, 2013
Antibodies to watch in 2013: Mid-year updateJanice M Reichert
Mabs|October 9, 2010
Metrics for antibody therapeutics developmentJanice M Reichert
Mabs|January 13, 2010
mAb therapeutic products and risk managementJanice M Reichert
Mabs|January 13, 2010
Letter from the editorJanice M Reichert
Pageof 10

Showing results (1-10 of 92) with videos related to

Sort By:
Pageof 10
Current Opinion in Molecular Therapeutics|June 5, 2002
Therapeutic monoclonal antibodies: trends in development and approval in the USJanice M Reichert
Medecine Sciences : M/S|January 7, 2020
[Antibody therapeutics: an American view of an amazing present and future]Janice M Reichert
Mabs|March 2, 2011
Letter from the Editor: stratified medicineJanice M Reichert
Mabs|June 10, 2011
Bispecific antibodies and ADCs: Once and future kings?Janice M Reichert
Mabs|January 13, 2010
Letter from the editorJanice M Reichert
Current Pharmaceutical Biotechnology|December 17, 2008
Monoclonal antibodies as innovative therapeuticsJanice M Reichert
Mabs|June 4, 2013
Antibodies to watch in 2013: Mid-year updateJanice M Reichert
Mabs|October 9, 2010
Metrics for antibody therapeutics developmentJanice M Reichert
Mabs|January 13, 2010
mAb therapeutic products and risk managementJanice M Reichert
Mabs|January 13, 2010
Letter from the editorJanice M Reichert
Pageof 10